Market Research Logo

Oral Biologics Market by Therapy Type (Tumour Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, and Interleukin Inhibitors) by Indications (Arthritis, Asthma, Carcinoma, Crohn’s Disease, Diabetes, Enterocolitis, Multiple myeloma, Multiple sclerosis

Oral Biologics Market by Therapy Type (Tumour Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, and Interleukin Inhibitors) by Indications (Arthritis, Asthma, Carcinoma, Crohn’s Disease, Diabetes, Enterocolitis, Multiple myeloma, Multiple sclerosis, Psoriasis, Sarcoma, and Others) By Application (Inflammatory, Metabolic disorders, and Neoplastic) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn’s disease, and ulcerative colitis.

Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parental route and only guanylate cyclase-c agonist class of drug is approved oral biological in market.

However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.

Market Dynamics

Frequent research and development activities by key players for the development of novel oral biologics products and launch them in market is expected to boost global oral biologics market growth over the forecast period.

For instance, Allena Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, is involved in development of Reloxaliase, a non-absorbed, orally-administered enzyme for treatment of hyperoxaluria. Currently (June 2019), Reloxaliase is in Phase 2 clinical trial.

Furthermore, key players in the market are involved in strategic partnership and mergers for development of novel oral biologics products and gain its approval. Such strategic partnerships are expected to drive global oral biologics market growth.

For instance, in December 2017, Rani Therapeutics and Shire Plc. collaborated to conduct research and evaluate the application of RaniPill technology for the oral delivery of factor VIII therapy for Hemophilia A patients

In January 2017, Enteris BioPharma, Inc. and Ferring Pharmaceuticals entered into license agreement to leverage Enteris proprietary oral drug delivery platform Peptelligence, to develop an oral formulation of a peptide-based injectable therapeutic developed by Ferring.

Such strategies among key players may lead to development of novel oral biologics, which in turn is expected to drive global oral biologics market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of global oral biologics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global oral biologics market based on following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc. Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global oral biologics market
Detailed Segmentation:
  • Global Oral Biologics Market, By Drug Class:
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • Global Oral Biologics Market, By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
  • Global Oral Biologics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Oral Biologics Market, By Region:
  • North America
  • By Drug Class :
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Europe
  • By Drug Class :
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class :
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • By Drug Class:
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • By Drug Class :
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class :
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country/Region:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Novo Nordisk A/S*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Biocon Limited
  • Oramed Pharmaceuticals, Inc.
  • Rani Therapeutics
  • Entera Bio Ltd.
  • Allergan plc.
  • Emisphere Technologies, Inc.
  • Enteris BioPharma, Inc.
  • Chiasma, Inc.
  • Allena Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Disease Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
PEST Analysis
Adherence of Patients- Injectable Biologics
Regulatory Scenario
Limitations of Injectable Biologics
Epidemiology
Mechanism of Action- Pill Technology
Partnership/Collaboration/Acquisition/Agreement
4. Global Oral Biologics Market, By Drug Class, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Hormone
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Recombinant Enzyme
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Guanylate Cyclase-C Agonist
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Somatostatin Analogue
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
5. Global Oral Biologics Market, By Disease Indication, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
Diabetes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Hyperoxaluria
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Acromegaly
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
6. Global Oral Biologics Market, By Distribution Channel, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
7. Global Oral Biologics Market, By Region, 2016 – 2026 (US$ Mn)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
North America
Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
U.S.
Canada
Europe
Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC
Latin America
Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country/Region, 2016 – 2026 (US$ Mn)
Central Africa
South Africa
North Africa
Middle East
Market Size and Forecast, By Drug Class, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
GCC
Israel
Rest of Middle East
8. Competitive Landscape
Heat Map Analysis
Company Profiles
Novo Nordisk A/S
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Biocon Limited
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Oramed Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Rani Therapeutics
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Entera Bio Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Allergan plc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Emisphere Technologies, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Enteris BioPharma, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Chiasma, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Allena Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
9. Section
References
Research Methodology
About us and Sales Contact
*Browse 30 market data tables and 32 figures on “Oral Biologics Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report